Clinical Trials Browser

Phase 2 × Nasopharyngeal Carcinoma × Valganciclovir × Clear all

NCT07138989 2025-08-24

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections